US stock · Healthcare sector · Biotechnology
Company Logo

Bio-Techne Corporation

TECHNASDAQ

352.81

USD
-4.36
(-1.22%)
Market Closed
64.26P/E
39Forward P/E
2.48P/E to S&P500
13.842BMarket CAP
0.36%Div Yield
Upcoming Earnings
3 Aug-8 Aug
Shares Short
5/13/22
557.99k
Short % of Float
1.62%
Short % of Shares Outs.
1.42%
% Held by Insiders
0.66%
% Held by Institutions
97.45%
Beta
1.21
PEG Ratio
3.08
52w. high/low
543.85/335.02
Avg. Daily Volume
0.23M
Return %
Stock
S&P 500
1 year
(15.57)
(6.01)
3 years
77.02
39.24
5 years
214.06
63.25
Scale: |
High
Low
72.00
54.49
82.92
57.10
69.95
45.38
69.74
55.63
86.43
62.04
76.02
63.08
94.78
62.55
97.15
82.51
114.56
83.90
117.42
79.95
136.39
95.68
206.04
128.06
223.28
134.59
326.44
155.17
543.85
310.62
519.05
335.02
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
5.19
5.67
6.58
6.98
7.22
7.82
8.52
8.43
9.70
12.19
13.42
15.09
17.16
18.90
19.34
24.03
27.50
Earnings per share
1.88
2.16
2.65
2.78
2.95
3.03
3.04
3.06
3.01
2.90
2.81
2.04
3.37
2.54
6.00
3.62
5.75
FCF per share
2.07
2.09
2.53
2.77
2.86
3.33
3.27
2.74
3.33
3.22
3.41
3.44
3.99
4.13
4.02
7.95
7.71
Dividends per share
- -
- -
- -
0.75
1.03
1.07
1.11
1.18
1.23
1.27
1.28
1.27
1.28
1.28
1.28
1.28
1.28
CAPEX per share
0.12
0.20
0.42
0.17
0.12
0.10
0.16
0.61
0.37
0.54
0.45
0.41
0.56
0.67
1.35
1.14
1.09
Book Value per sh.
8.72
11.11
12.45
12.08
13.47
15.80
18.26
20.02
21.56
22.83
23.64
25.45
28.79
30.85
36.16
40.34
42.28
Comm.Shares outs.
39
39
39
38
37
37
37
37
37
37
37
37
37
38
38
39
39
Avg. annual P/E ratio
28.9
28.0
26.7
21.8
21.1
24.0
22.8
24.4
30.2
33.0
36.0
56.2
47.1
77.5
40.8
121.3
64.3
P/E to S&P500
1.6
1.6
1.2
0.3
1.0
1.5
1.5
1.4
1.7
1.7
1.6
2.4
1.9
3.2
1.1
4.0
2.5
Avg. annual div. yield
- -
- -
- -
1.2%
1.7%
1.5%
1.6%
1.6%
1.4%
1.3%
1.3%
1.1%
0.8%
0.6%
0.5%
0.3%
0.3%
Revenue (m)
203
223
257
264
269
290
315
311
358
452
499
563
643
714
739
931
1,076
Operating margin
53.6%
55.6%
56.1%
57.1%
58.1%
56.2%
52.8%
51.0%
44.7%
32.5%
30.2%
21.4%
21.2%
20.5%
21.3%
25.5%
26.3%
Depreciation (m)
7
7
7
8
8
9
12
12
19
37
43
60
64
78
83
88
100
Net profit (m)
73
85
104
105
110
112
112
113
111
108
104
76
126
96
229
140
225
Income tax rate
34.0%
34.0%
32.7%
32.3%
29.8%
31.9%
30.7%
29.9%
31.3%
30.1%
29.2%
32.0%
(0.2)%
14.2%
17.1%
5.8%
(19.8)%
Net profit margin
36.2%
38.1%
40.2%
39.9%
40.8%
38.7%
35.7%
36.2%
31.0%
23.8%
20.9%
13.5%
19.6%
13.5%
31.0%
15.1%
20.9%
Working capital (m)
132
196
238
240
184
212
311
377
443
209
200
213
319
311
414
358
426
Long-term debt (m)
12
- -
- -
- -
- -
- -
- -
- -
7
73
92
344
339
493
344
396
303
Equity (m)
340
438
487
456
502
586
674
738
795
847
879
950
1,079
1,166
1,381
1,563
1,714
ROIC
20.8%
19.4%
21.3%
23.1%
21.9%
18.7%
16.4%
15.1%
13.3%
10.6%
9.8%
5.7%
9.0%
6.4%
12.8%
7.3%
14.1%
Return on capital
30.0%
28.3%
30.3%
32.9%
30.2%
26.7%
22.5%
20.6%
18.7%
14.6%
13.2%
7.7%
8.5%
7.1%
14.6%
7.2%
10.9%
Return on equity
21.6%
19.4%
21.3%
23.1%
21.9%
19.2%
16.7%
15.3%
14.0%
12.7%
11.9%
8.0%
11.7%
8.2%
16.6%
9.0%
13.2%
Plowback ratio
100.0%
100.0%
100.0%
73.2%
65.0%
64.7%
63.5%
61.4%
59.1%
56.3%
54.4%
37.8%
62.0%
49.7%
78.7%
64.7%
77.7%
Div.&Repurch./FCF
18.2%
(1.8)%
57.7%
114.1%
47.6%
33.9%
54.3%
45.4%
36.9%
39.4%
37.5%
36.9%
32.1%
40.8%
64.5%
30.1%
36.7%
Capital Structure
9 May · 2022 | Q3
All numbers in millions
Total liabilities
$ 587
Total assets
$ 2,300
Long-term debt
$ 303
Cash and equiv.
$ 161
Goodwill
$ 828
Retained earnings
$ 1,133
Common stock
39
Enterprise Value
$ 13,984
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
166
271
232
Receivables
137
123
145
Inventory
91
103
117
Other
18
70
115
Current assets
413
521
511
Acc. Payable
16
23
29
Debt due
13
22
24
Other
73
62
99
Current liabilities
102
107
152
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
26.04%
13.69%
13.14%
Cash flow
100.60%
29.97%
14.41%
Earnings
(38.76)%
35.47%
11.95%
Dividends
1.47%
1.19%
2.16%
Book value
13.16%
13.33%
9.87%
Insider Trading
Type
Shares
Date
Baumgartner Robert V
Purchase
300
05/10/22
Kelderman Kim
Exempt
1,989
02/08/22
Kelderman Kim
Exempt
1,989
02/08/22
Geist William
Award
3,978
02/01/22
Geist William
Award
2,984
02/01/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
183
185
195
176
739
2021
204
224
244
259
931
2022
258
269
290
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.38
3.13
0.95
1.54
6.00
2021
0.86
1.19
1.18
0.39
3.62
2022
1.78
2.04
1.55
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.32
0.32
0.32
0.32
1.28
2021
0.32
0.32
0.32
0.32
1.28
2022
0.32
0.32
0.32
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Charles Kummeth
Full-time employees:
2,700
City:
Minneapolis
Address:
614 McKinley Pl NE
IPO:
Feb 9, 1989
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.